Natera Inc - Asset Resilience Ratio
Natera Inc (NTRA) has an Asset Resilience Ratio of 0.00% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Natera Inc PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2025)
This chart shows how Natera Inc's Asset Resilience Ratio has changed over time. See Natera Inc balance sheet quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Natera Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Natera Inc market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Natera Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Natera Inc Industry Peers by Asset Resilience Ratio
Compare Natera Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Prodia Widyahusada Tbk PT
JK:PRDA |
Diagnostics & Research | 7.82% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
|
Optipharm.CO.LTD
KQ:153710 |
Diagnostics & Research | 18.64% |
|
Avricore Health Inc
V:AVCR |
Diagnostics & Research | 1.78% |
|
Check-Cap Ltd
F:7CC |
Diagnostics & Research | 2.90% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
Annual Asset Resilience Ratio for Natera Inc (2013–2025)
The table below shows the annual Asset Resilience Ratio data for Natera Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.00% | $0.00 | $2.51 Billion | -- |
| 2024-12-31 | 1.37% | $22.69 Million | $1.66 Billion | -15.06pp |
| 2023-12-31 | 16.43% | $236.88 Million | $1.44 Billion | -14.57pp |
| 2022-12-31 | 31.00% | $432.30 Million | $1.39 Billion | -36.12pp |
| 2021-12-31 | 67.12% | $829.90 Million | $1.24 Billion | -6.76pp |
| 2020-12-31 | 73.87% | $688.61 Million | $932.15 Million | +8.81pp |
| 2019-12-31 | 65.06% | $379.06 Million | $582.66 Million | +24.99pp |
| 2018-12-31 | 40.07% | $107.46 Million | $268.17 Million | -9.43pp |
| 2017-12-31 | 49.51% | $106.25 Million | $214.61 Million | -12.61pp |
| 2016-12-31 | 62.11% | $130.86 Million | $210.68 Million | -13.89pp |
| 2015-12-31 | 76.00% | $201.59 Million | $265.24 Million | +75.59pp |
| 2014-12-31 | 0.41% | $503.00K | $123.62 Million | +0.16pp |
| 2013-12-31 | 0.25% | $150.00K | $59.72 Million | -- |
About Natera Inc
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehe… Read more